THTatsunori Hanai

Tatsunori Hanai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatsunori Hanai has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy

    by Kenji Imai, Koji Takai, Masashi Aiba, Shinji Unome, Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu

    Aim: This study aimed to clarify the clinical characteristics of patients with advanced hepatocellular carcinoma (HCC) who transitioned to subsequent therapies following systemic therapy (ST). Methods: In total, 136 patients with unresectable HCC (26 hepatitis B, 47 hepatitis C and 63 others) receiving first‐line ST, including 31 patients treated with immune checkpoint inhibitors (ICIs), were enrolled. Clinical characteristics and adverse events observed during treatment, as well as overall survival (OS), progression‐free survival and post progression survival (PPS), were compared between patients who transitioned to subsequent therapies (2nd therapy group, n = 66) and those who did not (non‐2nd therapy group, n = 70). Results: Significant differences between the two groups were observed in OS (29.3 vs. 10.7 months, p < 0.001), PPS (11.3 vs. 2.9 months, p < 0.001), ALBI score (−2.48 vs. −2.34, p = 0.018), treatment with/without ICIs (24/42 vs. 7/63, p < 0.001), TNM stage (II/III/IVA/IVB; 15/26/7/18 vs. 3/27/10/30, p = 0.008) and the adverse events of appetite loss ( p = 0.009) and proteinuria ( p = 0.006). A favourable ALBI score ( p = 0.005), treatment with ICIs ( p = 0.002) and earlier TNM stage ( p = 0.027) identified by logistic regression analysis and TNM stage II in men and prothrombin time ≥ 105% in women by classification tree analysis were found to be associated with a higher likelihood of transitioning to subsequent therapies. Conclusions: Initiating systemic therapy, including ICIs, before clinical stage progression and preserving the hepatic reserve is crucial for ensuring a smooth transition to subsequent therapies. Registry and the Registration No. of the Study/Trial: N/A.

  • Open Access

    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study

    by Taisei Iwasa, Takao Miwa, Yuki Utakata, Mikita Oi, Mayu Asakura, Takumi Onishi, Masashi Aiba, Shinji Unome, Tatsunori Hanai, Makoto Shiraki, et al.

    Background: Overt hepatic encephalopathy (OHE) is a severe complication of liver cirrhosis. However, data on its incidence, prognostic significance, and associated risk factors in patients without OHE at baseline remain limited. Methods: A multicenter retrospective cohort study was conducted by reviewing records of hospitalized patients with cirrhosis at three institutions in Japan. OHE was defined as West Haven grade ≥ 2 and its incidence during the follow-up was estimated using the cumulative incidence function. Prognostic factors were assessed using Cox proportional hazards regression analysis, with OHE and hepatocellular carcinoma (HCC) development treated as time-dependent covariates. Independent predictors for OHE development were analyzed using fine-gray proportional hazards regression analysis. Results: Among 652 patients, the median age was 67 years, and 53% were male. The median model for end-stage liver disease (MELD) score was 9. During a median follow-up period of 3.2 years, 136 patients (21%) developed OHE and 183 patients (28%) died. The cumulative incidence of OHE at 1, 3, and 5 years was 8%, 16%, and 20%, respectively. Multivariable analysis demonstrated that OHE development (hazard ratio [HR], 3.07; 95% confidence interval [CI], 1.99–4.75) was a significant independent prognostic factor, regardless of age, sex, liver functional reserve, and HCC development. Furthermore, multivariable analysis identified lower body mass index, higher MELD score, lower albumin levels, and higher ammonia levels as independent predictors for OHE development. Conclusions: OHE development is common and increases mortality among patients with cirrhosis. Therefore, close monitoring of high-risk populations is warranted for early management of OHE.


  • Open Access

    Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis

    by Takao Miwa, Hajime Ueda, Teruo Miyazaki, Akira Honda, Tadashi Ikegami, Shinji Unome, Tatsunori Hanai, Yohei Shirakami, Masahito Shimizu

    Aim: Bile acid (BA) signaling plays an important role in the pathogenesis of hepatic encephalopathy (HE), including covert (CHE) and overt HE (OHE). However, few studies have examined its clinical impact in patients with cirrhosis. Methods: This retrospective study included patients with cirrhosis who underwent CHE assessment using a computer‐aided neuropsychiatric test. BAs were quantified using liquid chromatography‐tandem mass spectrometry. Patients were divided into high and low groups according to their BA levels. Independent factors, namely CHE, OHE development, and mortality, were assessed using logistic, Fine–Gray competing risk, and Cox proportional hazards regression models. Results: Among the 189 patients, the median age was 71 years, 74.1% were male, and 28.0% were diagnosed with CHE. During a median follow‐up period of 3.1 years, 15.9% ( n = 30) developed OHE, and 33.3% ( n = 63) died. Considering mortality as a competing risk, multivariable analysis identified a high conjugated primary BA level (subdistribution hazard ratio [HR] 3.44; 95% confidence interval [CI] 1.08–10.97) as an independent factor for OHE development. Additionally, a high non‐conjugated primary BA level (odds ratio 2.18; 95% CI 1.06–4.46) was an independent factor of CHE. Furthermore, a high conjugated primary BA level (HR 2.06; 95% CI 1.11–3.83) was an independent predictor of mortality. Conclusions: Elevated serum conjugated primary BA levels are an independent factor for OHE development and mortality in patients with cirrhosis. Additionally, elevated non‐conjugated primary BA levels were an independent factor for CHE in these patients.


  • Open Access

    Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study

    by Yuki Utakata, Takao Miwa, Masashi Aiba, Shinji Unome, Tatsunori Hanai, Kenji Imai, Yohei Shirakami, Koji Takai, Makoto Shiraki, Naoki Katsumura, et al.

    Identifying the risk of overt hepatic encephalopathy (OHE) in geriatric patients with cirrhosis remains challenging. This study aimed to investigate the independent factors for OHE development in geriatric cirrhosis and to establish a simple scoring model to identify individuals at risk for OHE. We conducted a retrospective review of geriatric patients with cirrhosis aged ≥ 80 years who were admitted between April 2006 and November 2022. Baseline parameters were assessed at the time of admission, and factors associated with OHE development were examined using Fine-Gray proportional hazards regression analysis, with mortality as a competing risk. Based on the factors associated with OHE development, a simple hepatic encephalopathy (sHE) score was calculated, and its efficacy was subsequently verified. Of the 270 patients analyzed, the median age was 83 years, and 63% were male. During a median follow-up of 1.8 years, 41 (15%) patients developed OHE and 120 (44%) patients died. Multivariable analysis revealed that serum albumin (sub-distribution hazard ratio [SHR], 0.51; 95% confidence interval [CI], 0.27–0.98; p = 0.042) and ammonia (SHR, 1.01; 95% CI, 1.00–1.02; p = 0.006) levels were independent factors for OHE development in geriatric cirrhosis. Based on the sHE score, the high-risk and intermediate-risk groups exhibited a high incidence of OHE, whereas those in the low-risk group rarely developed OHE. Serum albumin and ammonia levels were identified as independent risk factors for the development of OHE in geriatric cirrhosis. The sHE score was useful for stratifying the risk of OHE in the geriatric population.


  • Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis

    by Takao Miwa, Goki Suda, Ryosuke Tateishi, Tatsunori Hanai, Masatsugu Ohara, Yasuhiro Hagiwara, Shinji Unome, Kazuya Okushin, Mina Nakagawa, Naoya Sakamoto, et al.


  • Open Access

    Cachexia is an independent predictor of mortality in patients with cirrhosis

    by Takao Miwa, Goki Suda, Ryosuke Tateishi, Tatsunori Hanai, Masatsugu Ohara, Yasuhiro Hagiwara, Shinji Unome, Kazuya Okushin, Mina Nakagawa, Naoya Sakamoto, et al.

    Aim: Cachexia is a systemic response syndrome characterized by disabling wasting during disease progression. This study aimed to elucidate factors associated with cachexia in patients with cirrhosis and to examine the impact of cachexia on patient survival.Methods: This multicenter retrospective cohort study included patients with cirrhosis admitted to two distinct institutes in Japan. Cachexia was diagnosed according to the criteria proposed by the Asian Working Group for Cachexia. Factors associated with cachexia and the prognostic impact of cachexia were assessed using logistic regression and Cox proportional hazards regression, respectively.Results: Of the 723 patients enrolled (median [interquartile range] age, 71 [64–77] years; 456 [63%] were male; and 390 [54%] had viral hepatitis), 200 (28%) met the criteria for cachexia diagnosis, with the prevalence increasing with Child–Pugh class from A (17%) to B (40%) and C (66%). Multivariable logistic regression analysis revealed that age and indices of liver function reserve, including Child–Pugh score, were associated with cachexia, whereas sex, etiology of cirrhosis, and complications with hepatocellular carcinoma (HCC) were not. During a median follow‐up period of 3.2 years, 264 (37%) patients died. Multivariable Cox regression analyses showed that cachexia was independently associated with increased mortality (adjusted hazard ratio, 1.62; 95% confidence interval, 1.24–2.12), along with factors related to liver function, HCC, and alcohol‐associated liver disease as the etiology. [Correction added on 22 May 2025, after first online publication: The adjusted hazard ratio and confidence interval in the Results section of Abstract have been changed from ‘1.59; 95% and 1.43–1.77’ to ‘1.62; 95% and 1.24–2.12’.]Conclusions: Cachexia is associated with poor liver function in patients with cirrhosis and is an independent prognostic factor.


  • Open Access

    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey

    by Takao Miwa, Mio Tsuruoka, Hajime Ueda, Tamami Abe, Hiroki Inada, Yoshimi Yukawa-Muto, Masatsugu Ohara, Taeang Arai, Yasuyuki Tamai, Hiroshi Isoda, et al.

    Background: Covert hepatic encephalopathy (CHE) leads to devastating outcomes in patients with cirrhosis. This study aims to elucidate the current management and future perspectives of CHE in Japan. Methods: A questionnaire-based cross-sectional study was conducted among physicians involved in managing cirrhosis in Japan. The primary aim was to elucidate the real-world management of CHE, including testing and treatment. Factors influencing the implementation of CHE testing were analyzed using a logistic regression model. Limitations and future perspectives for improving the management of CHE were also evaluated. Results: Of 511 physicians surveyed, 93.9% recognized CHE as a significant problem, and 86.9% agreed that it should be tested. Overall, 62.8% of physicians tested for CHE, whereas 37.2% did not. Multivariable analysis identified institutional factors and certifying board as significant determinants of CHE test implementation. The Stroop (68.2%) and neuropsychiatric tests (57.5%) were the most commonly used methods of identifying CHE. Among those who tested for CHE, 87.7% treated CHE; the most common treatments were lactulose (81.5%), rifaximin (76.3%), and branched-chain amino acids (70.4%). Among non-testers, the primary barrier was the time requirement for testing. Proposals to encourage CHE testing included the development of simple tests and integration of multidisciplinary teams. Conclusions: Most physicians involved in cirrhosis care in Japan recognize CHE as a significant problem that warrants testing. However, testing for CHE remains limited by institutional factors and physician specialties. Time requirements for CHE testing are the primary barrier, and simple tests and multidisciplinary teams are recommended to enhance CHE management.


  • Open Access

    Cachexia is an independent predictor of mortality in patients with hepatocellular carcinoma on systemic targeted therapy

    by Shinji Unome, Kenji Imai, Masashi Aiba, Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu


  • Open Access

    Psoas Muscle Index as an Independent Predictor of Survival in Patients with Hepatocellular Carcinoma Receiving Systemic Targeted Therapy

    by Kenji Imai, Koji Takai, Masashi Aiba, Shinji Unome, Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu

    Background: This study aimed to investigate the usefulness of the psoas muscle index (PMI) as an independent predictor of survival after systemic targeted therapy initiation in patients with hepatocellular carcinoma (HCC). Method: In total, 214 patients with HCC who underwent systemic targeted therapy at the Gifu University Hospital were enrolled. The correlation between the PMI and the skeletal muscle index (SMI) was assessed using Pearson’s correlation coefficient (PCC). The Cox proportional hazards model was employed to determine whether the PMI, along with the α-fetoprotein (AFP) level and the ALBI score, influenced survival; these variables were considered time-dependent covariates. The optimal PMI cut-off value that yielded the most significant differences in survival was determined using maximally selected statistics. Results: The PMI was significantly correlated with the SMI (PCC = 0.38 and p < 0.001 for women; PCC = 0.62 and p < 0.001 for men). The PMI independently influenced survival (hazard ratio: 0.852; 95% confidence interval: 0.755–0.962; and p < 0.001), along with established prognostic factors such as the AFP and the ALBI score. The optimal PMI cut-off values that yielded the most significant differences in survival were 2.86 cm2/m2 for women and 3.55 cm2/m2 for men, and these values significantly stratified patient outcomes for both sexes (p < 0.001). Conclusions: The PMI serves as a reliable surrogate for the SMI in assessing skeletal muscle mass and predicting survival.


  • Response to letter to the editor regarding: “Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis”

    by Tatsunori Hanai, Kayoko Nishimura, Shinji Unome, Takao Miwa, Yuki Nakahata, Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu